GGrantIndex
← Search

Core--Cellular therapy

$77,767P30FY2003CANIH

Fred Hutchinson Cancer Research Center, Seattle WA

Investigators

Linked publications, trials & patents

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

The Cellular Therapy Shared Resource is an integral part of the Consortium and plays a critical role in the Clinical Transplantation program. Cellular Therapy helps support research by providing four specific functions. First, the resource provides the critical instrumentation and technical expertise in apheresis collection, cell processing, cryopreservation, and the infusion of cells. Included within this objective are the development of new cell selection and culturing techniques in support of novel autologous and allogeneic treatment protocols. Second, Cellular Therapy provides large-scale processing capabilities in support of specific research studies involving human, primate, and canine cells. This again encompasses the development of novel cell selection approaches and the preclinical validation of such research procedures for implementation in clinical studies. Third, the laboratory performs quantitative flow cytometry analyses and in vitro colony forming assays on various cellular components utilized for both clinical and research studies. These data are useful in determining which specific cell populations may be correlated with specific clinical outcomes. This in turn helps to stimulate the development of novel graft engineering approaches and techniques that could improve future transplantation studies. Fourth, Cellular Therapy procures and provides both patient and normal donor specimens in support of research projects. These samples, obtained under IRB approved protocols from fresh specimens and from an already established Repository Specimens for Research Studies, will be extremely useful in helping Center investigators to define the mechanisms involved in engraftment, disease control, immune reconstitution, and graft-versus-host disease. This application requests continued support for a resource which fulfills an essential role for peer reviewed research.

View original record on NIH RePORTER →